William Blair Weighs in on Envista’s Q4 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – Equities researchers at William Blair raised their Q4 2025 earnings estimates for shares of Envista in a note issued to investors on Thursday, February 6th. William Blair analyst B. Vazquez now anticipates that the company will post earnings of $0.34 per share for the quarter, up from their prior estimate of $0.33. The consensus estimate for Envista’s current full-year earnings is $0.72 per share. William Blair also issued estimates for Envista’s Q1 2026 earnings at $0.23 EPS, Q2 2026 earnings at $0.24 EPS and Q3 2026 earnings at $0.23 EPS.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%.

Several other equities analysts have also recently weighed in on the company. Leerink Partnrs upgraded Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Morgan Stanley increased their price target on shares of Envista from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Thursday. Piper Sandler boosted their price objective on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday. Stifel Nicolaus increased their target price on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.21.

Envista Stock Performance

Shares of NVST stock opened at $21.76 on Friday. The stock has a market capitalization of $3.75 billion, a P/E ratio of -2.80, a PEG ratio of 1.82 and a beta of 1.34. The firm’s 50 day moving average is $19.96 and its 200 day moving average is $19.12. Envista has a 12 month low of $15.15 and a 12 month high of $24.79. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42.

Hedge Funds Weigh In On Envista

A number of large investors have recently modified their holdings of NVST. Iron Triangle Partners LP bought a new position in Envista during the third quarter valued at approximately $43,262,000. Point72 Asset Management L.P. bought a new position in shares of Envista during the 3rd quarter valued at $37,559,000. Polar Asset Management Partners Inc. lifted its stake in Envista by 375.6% in the third quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company’s stock worth $29,586,000 after purchasing an additional 1,182,450 shares during the last quarter. Franklin Resources Inc. boosted its position in Envista by 26.5% during the third quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock valued at $78,480,000 after buying an additional 830,861 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC purchased a new stake in Envista during the third quarter valued at about $14,965,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.